In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different etiologies in adults and children.
We are pleased to inform you about our first #webinar sessions❗ On October 30th we talked about #UTIPROPLUS and its use in uncomplicated #UTIs.
Utipro® Plus AF available for launch
We are pleased to announce the availability for launch of a new formulation of UTIPRO® PLUS, our product for uncomplicated UTIs.
